Product logins

Find logins to all Clarivate products below.


Peripheral Arterial Disease | Treatment Algorithms | Claims Data Analysis | US | 2018

Treatment of peripheral arterial disease (PAD) has not changed significantly in recent years, and the typically prescribed drug classes for the prevention of atherothrombotic events are awash with generic options. Merck & Co. launched Zontivity for PAD in 2014, but performance has been much lower than initially expected; Aralez Pharmaceuticals now has US rights to this product. PAD Treatment Algorithms presents insights into the treatment practices of a disease that holds huge market opportunity for an agent that significantly outperforms current treatment approaches.

QUESTIONS ANSWERED:

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed PAD patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed PAD patients?
  • How have Zontivity and generic rosuvastatin been integrated into the treatment algorithm?
  • What proportion of PAD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of PAD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with PAD?

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…